Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review

Shah, Hina; Ruppell, Evan; Bokhari, Rozan; Aland, Parag; Lele, Vikram; Ge, Connie; McIntosh, Lacey J.

doi:10.1016/j.ejro.2023.100477

Cited by 10 publications

(5 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radionuclide therapy has been a crucial advance in the treatment of various conditions. Recent research has highlighted the effectiveness of radionuclide therapy in treating cancer patients, particularly those with advanced, metastatic disease (3,4). Studies have shown that it can offer a survival benefit over conventional treatments, with promising long-term outcomes observed in both men and women.…”

Section: Editorial On the Research Topic Women In Radionuclide Therap...mentioning

confidence: 99%

Editorial: Women in radionuclide therapy: 2023

Lopci,

Matteucci

2024

Front. Nucl. Med.

View full text Add to dashboard Cite

Section: Editorial On the Research Topic Women In Radionuclide Therap...mentioning

confidence: 99%

Editorial: Women in radionuclide therapy: 2023

Lopci,

Matteucci

2024

Front. Nucl. Med.

View full text Add to dashboard Cite

“…The major drawback of this process is that the metal complex can be dissociated within the biological system due to enzymatic action. A few examples of chelators are dodecane tetra acetic acid-based chelators (DOTA) (used for 68 Ga, 111 In, 188 Re labeling), 1,4,7- triazacyclononane-N,N′,N″-triacetic acid-based chelators (NOTA) (used for 67 Ga/ 68 Ga and 64 Cu labeling), diethylenetriaminepentaacetic acid based chelators (DTPA) (used for 99m Tc, 111 In, and 68 Ga labeling), etc. 45 Another approach in chelator-based radiolabeling is the ionophore-based method, wherein an ionophore ligand forms an ionophore complex with a radiometal.…”

Section: Chelator-based Radiolabelingmentioning

confidence: 99%

“…Although more than 100 alpha emitting radionuclides are available, the majority of them have inappropriate half-lives for therapeutic use and/or noneconomical production routes. Some may exhibit unsuitable chemical properties that restrict their applicability in nuclear medicine. , Presently, radium-223,224 ( 223,224 Ra), thorium-226,227 ( 227,226 Th), actinium-225 ( 225 Ac), astatine-211 ( 211 At), bismuth-212, 213 ( 212,213 Bi) are the α-emitters are used for therapy. Table summarizes the nuclear properties of these α-emitters.…”

Section: Radionuclides For Nanoscale Brachytherapymentioning

confidence: 99%

“…Some may exhibit unsuitable chemical properties that restrict their applicability in nuclear medicine. 67 , 68 Presently, radium-223,224 ( 223,224 Ra), thorium-226,227 ( 227,226 Th), actinium-225 ( 225 Ac), astatine-211 ( 211 At), bismuth-212, 213 ( 212,213 Bi) are the α-emitters are used for therapy. Table 2 summarizes the nuclear properties of these α-emitters.…”

Section: Radionuclides For Nanoscale Brachytherapymentioning

confidence: 99%

See 1 more Smart Citation

Cancer Brachytherapy at the Nanoscale: An Emerging Paradigm

Ghosh,

Lee,

Hsu

et al. 2023

Chemical & Biomedical Imaging

View full text Add to dashboard Cite

Brachytherapy is an established treatment modality that has been globally utilized for the therapy of malignant solid tumors. However, classic therapeutic sealed sources used in brachytherapy must be surgically implanted directly into the tumor site and removed after the requisite period of treatment. In order to avoid the trauma involved in the surgical procedures and prevent undesirable radioactive distribution at the cancerous site, welldispersed radiolabeled nanomaterials are now being explored for brachytherapy applications. This emerging field has been coined "nanoscale brachytherapy". Despite present-day advancements, an ongoing challenge is obtaining an advanced, functional nanomaterial that concurrently incorporates features of high radiolabeling yield, short labeling time, good radiolabeling stability, and long tumor retention time without leakage of radioactivity to the nontargeted organs. Further, attachment of suitable targeting ligands to the nanoplatforms would widen the nanoscale brachytherapy approach to tumors expressing various phenotypes. Molecular imaging using radiolabeled nanoplatforms enables noninvasive visualization of cellular functions and biological processes in vivo. In vivo imaging also aids in visualizing the localization and retention of the radiolabeled nanoplatforms at the tumor site for the requisite time period to render safe and effective therapy. Herein, we review the advancements over the last several years in the synthesis and use of functionalized radiolabeled nanoplatforms as a noninvasive substitute to standard brachytherapy sources. The limitations of present-day brachytherapy sealed sources are analyzed, while highlighting the advantages of using radiolabeled nanoparticles (NPs) for this purpose. The recent progress in the development of different radiolabeling methods, delivery techniques and nanoparticle internalization mechanisms are discussed. The preclinical studies performed to date are summarized with an emphasis on the current challenges toward the future translation of nanoscale brachytherapy in routine clinical practices.

show abstract

“…186 Re and 188 Re have practical therapeutic applications and have been tested in pre-clinical to phase-two clinical trials. Examples are [ 186/188 Re]-perrhenate for thyroid, breast and prostate cancer treatment; [ 188 Re]-DMSA for metastatic bone cancer and medullary carcinoma; [ 186 Re-MAG 3 ] for metastatic bone pain (Ogawa et al, 2005); and [ 186/188 Re]-HEDP for metastatic bone cancer, commercially known as 186 Re-etidronate (Tripunoski et al, 2022;Shah et al, 2023). The potential of merging both Re and Tc into a single entity leads to a 'theranostic pair' (Kleynhans et al, 2023), which is a complex containing both therapeutic and imaging capability (Frei et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Time-series analysis of rhenium(I) organometallic covalent binding to a model protein for drug development

Jacobs,

Helliwell,

Brink

2024

IUCrJ

View full text Add to dashboard Cite

Metal-based complexes with their unique chemical properties, including multiple oxidation states, radio-nuclear capabilities and various coordination geometries yield value as potential pharmaceuticals. Understanding the interactions between metals and biological systems will prove key for site-specific coordination of new metal-based lead compounds. This study merges the concepts of target coordination with fragment-based drug methodologies, supported by varying the anomalous scattering of rhenium along with infrared spectroscopy, and has identified rhenium metal sites bound covalently with two amino acid types within the model protein. A time-based series of lysozyme-rhenium-imidazole (HEWL-Re-Imi) crystals was analysed systematically over a span of 38 weeks. The main rhenium covalent coordination is observed at His15, Asp101 and Asp119. Weak (i.e. noncovalent) interactions are observed at other aspartic, asparagine, proline, tyrosine and tryptophan side chains. Detailed bond distance comparisons, including precision estimates, are reported, utilizing the diffraction precision index supplemented with small-molecule data from the Cambridge Structural Database. Key findings include changes in the protein structure induced at the rhenium metal binding site, not observed in similar metal-free structures. The binding sites are typically found along the solvent-channel-accessible protein surface. The three primary covalent metal binding sites are consistent throughout the time series, whereas binding to neighbouring amino acid residues changes through the time series. Co-crystallization was used, consistently yielding crystals four days after setup. After crystal formation, soaking of the compound into the crystal over 38 weeks is continued and explains these structural adjustments. It is the covalent bond stability at the three sites, their proximity to the solvent channel and the movement of residues to accommodate the metal that are important, and may prove useful for future radiopharmaceutical development including target modification.

show abstract

Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review

Cited by 10 publications

References 124 publications

Editorial: Women in radionuclide therapy: 2023

Editorial: Women in radionuclide therapy: 2023

Cancer Brachytherapy at the Nanoscale: An Emerging Paradigm

Time-series analysis of rhenium(I) organometallic covalent binding to a model protein for drug development

Contact Info

Product

Resources

About